AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
27. Juni 2023 08:45 ET
|
AIM ImmunoTech Inc.
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient enrollment expected to commence before the end of 2023 OCALA, Fla.,...
AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
14. Juni 2023 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments
12. Juni 2023 08:45 ET
|
AIM ImmunoTech Inc.
Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of Nebraska for Phase 2 study of Ampligen® for the...
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
15. Mai 2023 08:45 ET
|
AIM ImmunoTech Inc.
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023– Lead clinical program, Phase 2 locally advance pancreatic...
AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast
09. Mai 2023 08:50 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
12. April 2023 08:35 ET
|
AIM ImmunoTech Inc.
Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- AIM...
AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions
04. April 2023 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
03. April 2023 06:30 ET
|
AIM ImmunoTech Inc.
– Company continues to execute across development pipeline of high-value indications with 12 active clinical programs – Well-positioned to achieve multiple near-term, value-driving milestones –...
AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise
30. März 2023 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
27. März 2023 09:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...